---
schema_version: "secwatch.filing_event.v1"
accession: "0000320017-25-000063"
form_type: "8-K"
ticker: "LSTA"
cik: "0000320017"
company_name: "LISATA THERAPEUTICS, INC."
filed_at: "2025-10-08T23:59:59+00:00"
generated_at: "2026-05-17T04:22:18.168237+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Lisata grants Catalent non-exclusive license for certepetide ADC payload; up to $10.5M milestones

## Summary
- Granted Catalent non-exclusive license to use certepetide as ADC payload in SMARTag platform; Catalent assumes all R&D/commercial costs.
- Eligible for up to $10.5M in development milestone payments plus tiered revenue sharing on future sales/partnerships.
- Also entitled to portion of sublicense consideration received by Catalent.
- Catalent may terminate agreement on 30 days notice; also grants Lisata ROFN for out-licensing of resulting assets.

## SEC filing metadata
- accession: 0000320017-25-000063
- form_type: 8-K
- ticker: LSTA
- cik: 0000320017
- company_name: LISATA THERAPEUTICS, INC.
- filed_at: 2025-10-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/320017/000032001725000063/0000320017-25-000063-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/320017/000032001725000063/clbs-20251008.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000320017-25-000063
- JSON: https://secwatch.observer/filing/0000320017-25-000063.json
- Plain text: https://secwatch.observer/filing/0000320017-25-000063.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.